- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06639958
Studie různých programů, které pomohou VŠEM pacientům s užíváním udržovací medicíny doma
Strategie zvýšení přilnavosti 6MP založené na riziku u dětí, dospívajících a mladých dospělých se VŠEMI – pilotní studie
This clinical trial tests different programs to help patients with acute lymphoblastic leukemia (ALL) remember to take their medications during maintenance therapy at home. One problem with ALL maintenance treatment is remembering to take medicines at home like patients are supposed to. In maintenance, a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home. In this study, 6MP prescriptions are filled into a special medication bottle called MEMS® which is fitted with a special cap called TrackCap™ that electronically records when the medication bottle is opened. Researchers are trying a new program to help patients be better at taking their 6MP like they're supposed to. This new program may help patients to remember to take their 6MP medication.
Přehled studie
Postavení
Intervence / Léčba
- Postup: Biospecimen Collection
- Jiný: Questionnaire Administration
- Lék: Mercaptopurine
- Jiný: Informational Intervention
- Jiný: Media Intervention
- Jiný: Media Intervention
- Jiný: Medical Device Usage and Evaluation
- Behaviorální: Training and Education
- Behaviorální: Compliance Monitoring
- Behaviorální: Compliance Monitoring
- Behaviorální: Telephone-Based Intervention
- Behaviorální: Telephone-Based Intervention
- Behaviorální: Telephone-Based Intervention
- Behaviorální: Telephone-Based Intervention
- Jiný: Health Promotion and Education
Detailní popis
PRIMARY OBJECTIVES:
I. Collect data on the feasibility of a phase 3 adherence-enhancing 2 parallel 2-arm randomized clinical trial.
Ia. Estimate participation rates, refusal reasons, and attrition rates. Ib. Evaluate rates of completeness of all aspects of the study (surveys [rates of missing elements]; MEMS® TrackCap™ return rates; maintenance form return rates from site clinical research assistants [CRAs]; blood samples for pharmacogenetics and deoxyribonucleic acid [DNA]-incorporated thioguanine nucleotide [DNA-TG] levels).
SECONDARY OBJECTIVES:
I. Among baseline non-adherers, estimate the impact of ultra-intensified intervention package (U-iIP) versus (vs.) intervention package (IP) on 6MP adherence.
II. Among baseline adherers, estimate the impact of patient-empowered intervention package (pIP) vs. education alone (EDU) on 6MP adherence.
OUTLINE:
Patients receive the Patient Supply Kit containing an empty MEMS® medication bottle with TrackCap™ with child resistant medication bottles and child resistant standard caps, and written instructions for the patient and pharmacist, along with their 6MP prescription. Beginning on day 1 cycle 1 of Maintenance Therapy, patients start using the MEMS® medication bottle with TrackCap™. Clinical research assistants contact patients and parents by telephone the next day to confirm that TrackCap™ is being used, to identify any obstacles, and to determine solutions. Patients are instructed to return the first MEMS® TrackCap™ to the clinic on day 1 of Maintenance cycle 2. Patients are then assigned to 1 of 2 groups based on baseline adherence rates (adherers [adherence rate >= 95%] and non-adherers [adherence rate < 95%]).
NON-ADHERERS: Patients are randomized to 1 of 2 arms during cycle 2 of Maintenance therapy.
ARM I (IP): Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the multimedia interactive patient/parent/other adult education (MIPE) program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. A designated parent/other adult is selected and trained briefly in prompting and supervising the patient to take 6MP daily by the CRA on day 1 of Maintenance cycle 3. Patients also receive customized printed medication schedules approximately every 4 weeks (days 1, 29, and 57) during Maintenance cycles 3-5 (during scheduled clinic visits) from their healthcare provider. Patients and/or the parent/other adult receive automated customized electronic reminders delivered via smartphone according to the patient's electronic 6MP schedule. Once the designated parent/other adult receives the customized electronic reminder for 6MP, they are instructed to prompt initiation of the 6MP dose (if necessary), and to supervise the ingestion of the prescribed 6MP (in all instances). If the patient is not present when the dose of 6MP is due, the patient receives a call from the designated parent/other adult to prompt initiation of the dose. Patients and designated parents/other adults will be instructed to electronically indicate when 6MP has been taken (indicative of directly supervised therapy [DST] execution). Additionally, patients undergo blood sample collection on the study.
ARM II (U-iIP): Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. A designated parent/other adult is selected and trained briefly in prompting and supervising the patient to take 6MP daily by the CRA on day 1 of Maintenance cycle 3. Patients also receive customized printed medication schedules approximately every 4 weeks (days 1, 29, and 57) during Maintenance cycles 3-5 (during scheduled clinic visits) from their healthcare provider. Patients and/or the parent/other adult receive automated customized electronic reminders delivered via smartphone according to the patient's electronic 6MP schedule. Once the designated parent/other adult receives the reminder for 6MP, they are instructed to prompt initiation of the 6MP dose (if necessary), and to supervise the ingestion of the prescribed 6MP (in all instances). If the patient is not present when the dose of 6MP is due, the patient receives a call from the designated parent/other adult to prompt initiation of the dose. Patients and designated parents/other adults will be instructed to electronically indicate when 6MP has been taken (indicative of DST execution). If there is no response by the designated parent/other adult indicating 6MP ingestion within 1 hour of the scheduled time, additional automated reminders are sent. The Adherence Study Coordinating Center will evaluate electronic responses (indicative of DST execution) every 4 weeks. The DST response rates will be communicated to the COG sites, identifying the patients as low DST responders (response rate: < 85%) or high DST responders (response rate: ≥ 85%), along with instructions to serve as a guideline for communicating these results when reviewing them with their patient. DST response rates will be reviewed with the patient every 4 weeks at the clinic visit by the healthcare provider for all U-iIP patients (irrespective of response rate). Patients (and their designated caregiver) receive booster MIPE videos to view on their smartphone every 4 weeks (Days 1, 29, and 57) during Maintenance cycles 3-5, with content that reinforces the importance of 6MP in treating leukemia, having a daily routine for 6MP ingestion, and executing/confirming directly supervised therapy (DST) with each dose, and review common barriers to 6MP ingestion and DST execution (e.g., patient away from home, change in daily schedule), address additional barriers significantly associated with DST execution, and feature examples of patients/other adults self-identifying barriers (e.g., parent not always home at time of 6MP, lack of organizational skills, etc.), and provide specific steps to overcome the barriers. Additionally, patients undergo blood sample collection on the study.
ADHERERS: Patients are randomized to 1 of 2 arms during cycle 2 of Maintenance therapy.
ARM III (EDU: Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. Additionally, patients undergo blood sample collection on the study.
ARM IV (pIP): Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. On day 1 of Maintenance cycle 3, patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic. On day 1 of Maintenance cycle 3, the patient and a designated parent/other adult are trained to set daily reminders on their smartphones at the time the 6MP is due, and to use the "snooze" function to allow repeated reminders in case the medication cannot be taken when the alarm first goes off. The designated parent/other adult is also trained briefly by the CRA in prompting and supervising the patient to take 6MP daily. Once the designated parent/other adult hears the smartphone alarm for 6MP, they are instructed to prompt initiation of the 6MP dose (if necessary), and to supervise the ingestion of the prescribed 6MP (in all instances). If the patient is not present when the dose of 6MP is due, the patient receives a call from the designated parent/other adult to prompt initiation of the dose. Additionally, patients undergo blood sample collection on the study.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- Children's Hospital of Alabama
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Oakland, California, Spojené státy, 94611
- Kaiser Permanente-Oakland
-
-
Delaware
-
Wilmington, Delaware, Spojené státy, 19803
- Alfred I duPont Hospital for Children
-
-
Florida
-
Fort Myers, Florida, Spojené státy, 33908
- Golisano Children's Hospital of Southwest Florida
-
Jacksonville, Florida, Spojené státy, 32207
- Nemours Children's Clinic-Jacksonville
-
Orlando, Florida, Spojené státy, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Spojené státy, 32803
- AdventHealth Orlando
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Riley Hospital for Children
-
-
Maine
-
Bangor, Maine, Spojené státy, 04401
- Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21215
- Sinai Hospital of Baltimore
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- C S Mott Children's Hospital
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Spojené státy, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Spojené státy, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Spojené státy, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Spojené státy, 89502
- Renown Regional Medical Center
-
-
New York
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Children's Hospital of Philadelphia
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Spojené státy, 29203
- Prisma Health Richland Hospital
-
-
Texas
-
Austin, Texas, Spojené státy, 78723
- Dell Children's Medical Center of Central Texas
-
San Antonio, Texas, Spojené státy, 78229
- Methodist Children's Hospital of South Texas
-
-
Virginia
-
Falls Church, Virginia, Spojené státy, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Spojené státy, 23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Tacoma, Washington, Spojené státy, 98431
- Madigan Army Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Spojené státy, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age: >= 10 years and =< 25 years
- Previously enrolled onto AALL1732
- Consented to the AALL1732 mercaptopurine adherence correlative study
- Maintenance therapy has not yet begun
- English or Spanish-speaking (patient and parent/other adult)
- Planning to receive 6MP (as tablets) during maintenance phase of therapy
- Able and willing to use the MEMS® TrackCap™ (e.g., not using a pillbox or prescribed liquid 6MP)
- Has a designated parent/other adult who is willing to enter into a mutual agreement with the patient to participate in a daily supervised medication administration routine
- Patient/parent/other adult must be willing to use a smartphone to receive medication reminders
- Receiving treatment at a Children's Oncology Group (COG) institution in the United States
Exclusion Criteria:
-
Patients who have previously participated in or are currently participating in another intervention clinical trial designed to improve adherence
-
Regulatory requirements
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Adherers arm III (EDU)
Patients receive another Patient Supply Kit and MEMS® TrackCap™ to use on day 1 of Maintenance cycle 3 and for the remaining duration of the study. Patients and their caregiver view the MIPE program that features video clips of ALL patients and their parents/other adults discussing Maintenance treatment in the clinic on day 1 of cycle 3. Additionally, patients undergo blood sample collection on the study. |
Undergo blood sample collection
Ostatní jména:
Ancillary studies Receive Patient Supply Kit View MIPE program videos Review booster MIPE videos Use MEMS® with TrackCap™ Undergo training for prompting and supervising 6MP |
|
Experimentální: Adherers arm IV (pIP)
See Detailed Description. |
Undergo blood sample collection
Ostatní jména:
Ancillary studies Given PO
Ostatní jména:
Receive Patient Supply Kit View MIPE program videos Review booster MIPE videos Use MEMS® with TrackCap™ Undergo training for prompting and supervising 6MP Receive DST Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits Receive automated customized electronic reminders via smartphone Receive additional automated reminders Manually activate daily smartphone reminders with successive alerts (using the "snooze" function) Receive electronic reminders with successive alerts (using the "snooze" function) |
|
Experimentální: Non-adherers arm I (IP)
See Detailed Description. |
Undergo blood sample collection
Ostatní jména:
Ancillary studies Given PO
Ostatní jména:
Receive Patient Supply Kit View MIPE program videos Review booster MIPE videos Use MEMS® with TrackCap™ Undergo training for prompting and supervising 6MP Receive DST Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits Receive automated customized electronic reminders via smartphone Receive additional automated reminders Manually activate daily smartphone reminders with successive alerts (using the "snooze" function) Receive electronic reminders with successive alerts (using the "snooze" function) Receive customized printed medication schedules |
|
Experimentální: Non-adherers arm II (U-iIP)
See Detailed Description. |
Undergo blood sample collection
Ostatní jména:
Ancillary studies Given PO
Ostatní jména:
Receive Patient Supply Kit View MIPE program videos Review booster MIPE videos Use MEMS® with TrackCap™ Undergo training for prompting and supervising 6MP Receive DST Healthcare provider reviews DST response rates with the patient and any challenges they are having with 6MP adherence every 4 weeks at clinic visits Receive automated customized electronic reminders via smartphone Receive additional automated reminders Manually activate daily smartphone reminders with successive alerts (using the "snooze" function) Receive electronic reminders with successive alerts (using the "snooze" function) Receive customized printed medication schedules |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Participation
Časové okno: At baseline (by day 1 of maintenance chemotherapy)
|
Will calculate and report the proportion of patients eligible for the study who participate and will report a corresponding 95% confidence interval. |
At baseline (by day 1 of maintenance chemotherapy)
|
|
Refusal reasons
Časové okno: At baseline (by day 1 of maintenance chemotherapy)
|
A single question in a study case report form prompts refusal reason. For each available reason, will calculate and report the proportion of patients reporting that refusal reason as well as corresponding 95% confidence intervals. |
At baseline (by day 1 of maintenance chemotherapy)
|
|
Attrition
Časové okno: By 60 weeks from day 1 of maintenance chemotherapy
|
Will calculate and report the proportion of patients who drop out of the study prior to completion among those eligible and enrolled and will report the corresponding 95% confidence interval. |
By 60 weeks from day 1 of maintenance chemotherapy
|
|
Completion of study measures
Časové okno: By 60 weeks from day 1 of maintenance chemotherapy
|
Will calculate and report the proportion of patients who complete the following measures by the end of the study follow-up period: study survey submission, MEMS® TrackCap™ return, maintenance form return, and blood sample submission. Will also report the corresponding 95% confidence intervals. |
By 60 weeks from day 1 of maintenance chemotherapy
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
6-mercaptopurine (6MP) adherence (baseline non-adherers)
Časové okno: By 60 weeks from day 1 of maintenance chemotherapy
|
Among baseline non-adherers, the proportion of days with protocol defined appropriate medication use during the study follow up period will be captured for each patient using the MEMS cap. Will calculate and report the mean proportion of adherence days by arm and the corresponding 95% confidence interval. |
By 60 weeks from day 1 of maintenance chemotherapy
|
|
6MP adherence (baseline adherers)
Časové okno: By 60 weeks from day 1 of maintenance chemotherapy
|
Among baseline adherers, protocol defined appropriate medication use during the study follow up period will be captured for each patient using the MEMS cap. Will calculate and report the proportion with >= 95% adherence over the study follow up period by arm with a corresponding 95% confidence interval. |
By 60 weeks from day 1 of maintenance chemotherapy
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Smita Bhatia, Children's Oncology Group
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary
- Onemocnění imunitního systému
- Novotvary podle histologického typu
- Hematologická onemocnění
- Lymfatická onemocnění
- Lymfoproliferativní poruchy
- Imunoproliferativní poruchy
- Leukémie, lymfoidní
- Leukémie
- Hemická a lymfatická onemocnění
- Lymfoblastická leukémie-lymfom prekurzorových buněk
- Sloučeniny síry
- Organické chemikálie
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Puriny
- Zdravotní služby
- Zdravotnická zařízení pracovní síla a služby
- Preventivní zdravotní služby
- Socioekonomické faktory
- Charakteristiky populace
- Sloučeniny sulfhydrylu
- Výchova ke zdraví
- Merkaptopurin
- Vzdělávací status
- Manipulace se vzorkem
- azathiopurin
- Podpora zdraví
Další identifikační čísla studie
- ACCL2433
- UG1CA189955 (Grant/smlouva NIH USA)
- ACCL2433 (Jiný identifikátor: CTEP)
- NCI-2024-08458 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- COG-ACCL2433 (Jiný identifikátor: DCP)
- ACCL2433 (Jiný identifikátor: Children's Oncology Group)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .